Total Payments
$128,181
2024 Payments
$890.00
Companies
14
Transactions
137
Payment Breakdown by Category
Other$49,743 (38.8%)
Consulting$34,467 (26.9%)
Research$32,068 (25.0%)
Travel$7,356 (5.7%)
Food & Beverage$4,501 (3.5%)
Education$46.91 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $46,543 | 20 | 36.3% |
| Consulting Fee | $34,467 | 10 | 26.9% |
| Unspecified | $32,068 | 9 | 25.0% |
| Travel and Lodging | $7,356 | 41 | 5.7% |
| Food and Beverage | $4,501 | 55 | 3.5% |
| Honoraria | $3,200 | 1 | 2.5% |
| Education | $46.91 | 1 | 0.0% |
Payments by Type
General
$96,113
128 transactions
Research
$32,068
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sunovion Pharmaceuticals Inc. | $49,721 | 85 | $0 (2020) |
| Genentech, Inc. | $24,232 | 2 | $0 (2020) |
| Avanir Pharmaceuticals, Inc. | $24,224 | 21 | $0 (2019) |
| F. Hoffmann-La Roche AG | $9,323 | 13 | $0 (2022) |
| ABBVIE INC. | $5,795 | 2 | $0 (2023) |
| Greenwich Biosciences, Inc. | $4,266 | 1 | $0 (2021) |
| Roche Products Limited | $3,899 | 6 | $0 (2019) |
| H. Lundbeck A S | $3,200 | 1 | $0 (2021) |
| Janssen Pharmaceuticals, Inc | $2,525 | 1 | $0 (2020) |
| Neurocrine Biosciences, Inc. | $890.00 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $890.00 | 1 | Neurocrine Biosciences, Inc. ($890.00) |
| 2023 | $5,750 | 1 | ABBVIE INC. ($5,750) |
| 2022 | $557.45 | 3 | F. Hoffmann-La Roche AG ($465.10) |
| 2021 | $7,492 | 3 | Greenwich Biosciences, Inc. ($4,266) |
| 2020 | $31,497 | 9 | Genentech, Inc. ($24,232) |
| 2019 | $14,262 | 19 | Avanir Pharmaceuticals, Inc. ($7,825) |
| 2018 | $18,286 | 29 | Sunovion Pharmaceuticals Inc. ($16,311) |
| 2017 | $49,446 | 72 | Sunovion Pharmaceuticals Inc. ($29,145) |
All Payment Transactions
137 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/24/2024 | Neurocrine Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $890.00 | General |
| 01/19/2023 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $5,750.00 | General |
| 12/07/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $45.44 | General |
| Category: NEUROSCIENCE | ||||||
| 03/31/2022 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $465.10 | Research |
| Study: A PHASE II MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, 24-WEEK, 3-ARM, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RO5285119 IN CHILDREN AND ADOLESCENTS AGE 5-17 WITH AUTISM SPECTRUM DISORDER ASD, A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY, AND SAFETY STUDY OF BALOVAPTAN IN ADULTS WITH AUTISM SPECTRUM DISORDER WITH A 2-YEAR OPEN-LABEL EXTENSION | ||||||
| 02/08/2022 | ITI, Inc. | CAPLYTA (Drug) | Education | In-kind items and services | $46.91 | General |
| Category: PSYCHIATRY | ||||||
| 12/27/2021 | Greenwich Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,265.50 | General |
| 12/06/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $26.65 | General |
| 09/14/2021 | H. Lundbeck A S | — | Honoraria | Cash or cash equivalent | $3,200.00 | General |
| 12/31/2020 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | — | In-kind items and services | $1,541.61 | Research |
| Study: V1a 2 IN PEDIATRIC AUTISM • Category: None | ||||||
| 12/31/2020 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | — | In-kind items and services | $1,130.21 | Research |
| Study: V1a 2 IN PEDIATRIC AUTISM and Phase III study of Balovaptan in Adults with ASD • Category: None | ||||||
| 12/15/2020 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Consulting Fee | Cash or cash equivalent | $2,525.00 | General |
| Category: Neuroscience | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | — | In-kind items and services | $595.56 | Research |
| Study: A Phase II Multi-center, Randomized, Double-blind, 24-Week, 3-Arm, Parallel Group, Placebo-controlled Study to Investigate the Efficacy and Safety of RO5285119 in Children and Adolescents Age 5-17 With Autism Spectrum Disorder ASD • Category: None | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | — | In-kind items and services | $410.32 | Research |
| Study: A Phase II Multi-center, Randomized, Double-blind, 24-Week, 3-Arm, Parallel Group, Placebo-controlled Study to Investigate the Efficacy and Safety of RO5285119 in Children and Adolescents Age 5-17 With Autism Spectrum Disorder ASD, A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY, AND SAFETY STUDY OF Balovaptan IN adults WITH AUTISM SPECTRUM DISORDER with a 2-year open-label extension • Category: None | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | — | In-kind items and services | $242.39 | Research |
| Study: A Phase II Multi-center, Randomized, Double-blind, 24-Week, 3-Arm, Parallel Group, Placebo-controlled Study to Investigate the Efficacy and Safety of RO5285119 in Children and Adolescents Age 5-17 With Autism Spectrum Disorder ASD, A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY, AND SAFETY STUDY OF Balovaptan IN adults WITH AUTISM SPECTRUM DISORDER with a 2-year open-label extension • Category: None | ||||||
| 09/29/2020 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $820.00 | General |
| Category: CNS | ||||||
| 09/04/2020 | Genentech, Inc. | Non-Covered Product (Drug) | — | Cash or cash equivalent | $4,286.25 | Research |
| Study: PHASE III STUDY OF BALOVAPTAN IN ADULTS WITH ASD • Category: None | ||||||
| 04/27/2020 | Genentech, Inc. | Non-Covered Product (Drug) | — | Cash or cash equivalent | $19,946.14 | Research |
| Study: PHASE III STUDY OF BALOVAPTAN IN ADULTS WITH ASD • Category: None | ||||||
| 12/07/2019 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Travel and Lodging | In-kind items and services | $515.26 | General |
| Category: None | ||||||
| 12/07/2019 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Travel and Lodging | In-kind items and services | $461.22 | General |
| Category: None | ||||||
| 12/07/2019 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Food and Beverage | In-kind items and services | $91.25 | General |
| Category: None | ||||||
| 12/03/2019 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,792.00 | General |
| Category: CNS | ||||||
| 12/03/2019 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $124.69 | General |
| Category: CNS | ||||||
| 12/03/2019 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Travel and Lodging | Cash or cash equivalent | $25.52 | General |
| Category: CNS | ||||||
| 08/21/2019 | Avanir Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $3,450.00 | Research |
| Study: AVA1407 Observational Study in IED | ||||||
| 08/08/2019 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $13.73 | General |
| Category: CNS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PHASE III STUDY OF BALOVAPTAN IN ADULTS WITH ASD | Genentech, Inc. | $24,232 | 2 |
| AVA1407 Observational Study in IED | Avanir Pharmaceuticals, Inc. | $3,450 | 1 |
| V1a 2 IN PEDIATRIC AUTISM | F. Hoffmann-La Roche AG | $1,542 | 1 |
| V1a 2 IN PEDIATRIC AUTISM and Phase III study of Balovaptan in Adults with ASD | F. Hoffmann-La Roche AG | $1,130 | 1 |
| A Phase II Multi-center, Randomized, Double-blind, 24-Week, 3-Arm, Parallel Group, Placebo-controlled Study to Investigate the Efficacy and Safety of RO5285119 in Children and Adolescents Age 5-17 With Autism Spectrum Disorder ASD, A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY, AND SAFETY STUDY OF Balovaptan IN adults WITH AUTISM SPECTRUM DISORDER with a 2-year open-label extension | F. Hoffmann-La Roche AG | $652.71 | 2 |
| A Phase II Multi-center, Randomized, Double-blind, 24-Week, 3-Arm, Parallel Group, Placebo-controlled Study to Investigate the Efficacy and Safety of RO5285119 in Children and Adolescents Age 5-17 With Autism Spectrum Disorder ASD | F. Hoffmann-La Roche AG | $595.56 | 1 |
| A PHASE II MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, 24-WEEK, 3-ARM, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RO5285119 IN CHILDREN AND ADOLESCENTS AGE 5-17 WITH AUTISM SPECTRUM DISORDER ASD, A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY, AND SAFETY STUDY OF BALOVAPTAN IN ADULTS WITH AUTISM SPECTRUM DISORDER WITH A 2-YEAR OPEN-LABEL EXTENSION | F. Hoffmann-La Roche AG | $465.10 | 1 |
About Dr. Eric Hollander, M.D
Dr. Eric Hollander, M.D is a Psychiatry healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/05/2007. The National Provider Identifier (NPI) number assigned to this provider is 1336288638.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Hollander, M.D has received a total of $128,181 in payments from pharmaceutical and medical device companies, with $890.00 received in 2024. These payments were reported across 137 transactions from 14 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($46,543).
Ad
Practice Information
- Specialty Psychiatry
- Location New York, NY
- Active Since 02/05/2007
- Last Updated 03/14/2014
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1336288638
Products in Payments
- LATUDA (Drug) $49,721
- Non-Covered Product (Drug) $36,989
- SPRAVATO (Drug) $2,525
- CAPLYTA (Drug) $46.91
- VRAYLAR (Drug) $45.44
- QUILLICHEW ER (Drug) $21.06
- VYVANSE (Drug) $10.63
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in New York
Dr. Manish Zinzuvadia, M.d, M.D
Psychiatry — Payments: $1.3M
Psychiatry $1.3M
Dr. Jianping Chen, M.d, M.D
Psychiatry — Payments: $1.1M
Psychiatry $1.1M
Dr. Ulla Laakso, Md, MD
Psychiatry — Payments: $957,236
Psychiatry $957,236
Dr. Kerry Sulkowicz, M.d, M.D
Psychiatry — Payments: $476,134
Psychiatry $476,134
Dr. Ralph Aquila, M.d, M.D
Psychiatry — Payments: $327,213
Psychiatry $327,213
Dr. Paul Eder, M.d, M.D
Psychiatry — Payments: $278,989
Psychiatry $278,989